Navigation Links
Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting

ffect profile, mean that, if approved, satraplatin will represent an important new therapy option for patients with advanced prostate cancer whose prior chemotherapy has failed."

The relative risk of disease progression favored satraplatin for all pre- specified patient subsets, including prior Taxotere use, geographies, and the presence or absence of pain. For each of the 20 subsets presented today, the reduction in relative risk of disease progression ranged from 26% to 46%, corresponding to hazard ratios between 0.74 and 0.54.

Disease progression in the SPARC trial was defined as the first occurrence of any of several types of progression, including radiologic tumor progression (RECIST for soft tissue lesions or two or more new lesions on a bone scan); skeletal-related events (including a bone fracture, bone surgery or initiation of bisphosphonates); symptomatic progression (pain, weight loss, worsening of performance status); or death from any cause. Approximately 37% of patients in the trial progressed by pain and approximately 36% progressed on radiologic evidence. The hazard ratio for PFS for the subset of patients with pain progression or death was 0.64 (95% CI: 0.51-0.79, p=0.0001), representing a 36% reduction in the relative risk of progression. The hazard ratio for PFS for the subset of patients with radiologic progression or death was 0.64 (95% CI: 0.51-0.81, p=0.0001), representing a 36% reduction in the relative risk of progression. The hazard ratio for PFS for the subset of patients who progressed in ways other than radiologic or pain progression was 0.86 (95% CI: 0.63-1.17, p > 0.05).

In accordance with the recommendation of the independent Data Monitoring Board for the SPARC trial, patients who have not progressed continue to be treated and all patients will be followed for overall survival. As previously communicated, the interim analysis for overall survival conducted in June 2006 showed a trend, although not statistically si
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
10. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:12/4/2009)STREAMWOOD, Ill., Dec. 4 Shared Imaging, LLC, an independent provider of CT, MRI and PET/CT systems and service programs for hospitals and healthcare providers, is excited to announce it has received
(Date:12/4/2009)WASHINGTON, Dec. 4 Chemistry World recently highlighted a new report published by the Pharmaceutical Research and Manufacturers of America ( PhRMA ) that identifies 97 new drugs and vaccines in
(Date:12/4/2009)Opposes use of imported drugs often stored in tin cans and car trunks ,, WASHINGTON, Dec. 4 Today, the senior advocacy group RetireSafe urged the Senate to defeat the Dorgan Importation plan encomp
Breaking Medicine Technology:Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care 2U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2RetireSafe Urges Senate to Defeat Senate Amendment 2793 -- Says Senator Dorgan's Drug Importation Plan Puts Seniors at Risk 2ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomyc 53677 1ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomyc 53677 2ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomyc 53677 3ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomyc 53677 4The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 1The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 2The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 3The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 4The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 5The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 6The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 7The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 8The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 9The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 10The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 11The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 12Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor 28TNF 29 Blockers 53670 1Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor 28TNF 29 Blockers 53670 2Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor 28TNF 29 Blockers 53670 3Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor 28TNF 29 Blockers 53670 4Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor 28TNF 29 Blockers 53670 5Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor 28TNF 29 Blockers 53670 6Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor 28TNF 29 Blockers 53670 7Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor 28TNF 29 Blockers 53670 8Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor 28TNF 29 Blockers 53670 9Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor 28TNF 29 Blockers 53670 10Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor 28TNF 29 Blockers 53670 11
...K--(BUSINESS WIRE)--May 29, 2007 - Pfizer said tod...types of cancer, such as,melanoma, thyroid, liver,... renal cell carcinoma (RCC) - a type of advanced k...American Society of,Clinical Oncology (ASCO) annua...sponds differently to treatment, so,it,s critical ...
...--(BUSINESS WIRE)--May 29, 2007 - Mitopharm Corpor...ts of a research paper,where Professor Dr. Robert ... B, the precursor of (-) Schisandrin B - a novel,d...n a research paper entitled "SCHISANDRIN B PROTECT...Y ENHANCING MYOCARDIAL,GLUTATHIONE ANTIOXIDANT STA...
Other Medicine Technology:New Pfizer Oncology Data Across Numerous Cancer Types to be,Presented at ASCO 2New Pfizer Oncology Data Across Numerous Cancer Types to be,Presented at ASCO 3New Pfizer Oncology Data Across Numerous Cancer Types to be,Presented at ASCO 4New Pfizer Oncology Data Across Numerous Cancer Types to be,Presented at ASCO 5Investigation Findings, Corroborated by Empirical Evidence of the,Schisandra Berry as Cardio-Tonic in Traditional Chinese Medicine,for Hundreds of Years, Support the Use of Schisandrin B in the,Prevention and Treatment of IHD 2Investigation Findings, Corroborated by Empirical Evidence of the,Schisandra Berry as Cardio-Tonic in Traditional Chinese Medicine,for Hundreds of Years, Support the Use of Schisandrin B in the,Prevention and Treatment of IHD 3
(Date:12/4/2009)ANAHEIM, Calif., Dec. 4 Pamela Bowen, Chief Information Officer at Crescent Healthcare, was selected as a finalist for the "Chief Innovation Officer" Appy Award for transforming Crescent,s business w
(Date:12/4/2009)STANFORD, Calif. A new study shows that muscle cells grown in the lab can restore an intestine,s ability to squeeze shut properly. The work, performed in dogs and rats, might ultimately help treat pa
(Date:12/4/2009)Rockville, MD "Why is it that men can be bastards and women must wear pearls and smile?" wrote author Lynn Hecht Schafran. The answer, according to an article in the Journal of Vision , may lie in
(Date:12/4/2009)Move a response to pressure from federal regulators to crack down on abuse of opioid medications , , FRIDAY, Dec. 4 (HealthDay News) -- The makers of 24 different prescription painkillers on F
(Date:12/4/2009)Whether the H1N1 virus will come back during winter isn,t known, CDC says, , , FRIDAY, Dec. 4 (HealthDay News) -- The number of states reporting widespread swine flu activity continued to decl
Breaking Medicine News(10 mins):Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4Health News:Are angry women more like men? 2Health News:Makers of Powerful Painkillers Present Safety Plans 2Health News:Swine Flu Continues to Wane 2
... a.m. ET -, EMERYVILLE, Calif., Feb. 11 Neurobio... ) today announced financial,results for its fisca...2007., Revenues for the second quarter of 2007 we...Dec. 31, 2007 versus,$5.7 million in the same peri...
...wo Little Hands Productions --,creators of the pop...ision,show designed to teach babies, toddlers and ...Language (ASL) -- will debut its second season at ... series two will continue building children,s ASL,...
...ew Solution to Increase Customer Revenues, Manage ...SE: MSY.L), the global application software and se...istan has gone live with Misys,Equation. The solut...th the bank,s 2008 strategy focused on sustaining ...
... Irvine Hires Agency for Public Relations, MISSIO...,today announces it now provides public relations ...gan in December 2007 on Web site mapping and,messa... the past year, and we,anticipate many more change...
...1 Kay Renz Public Relations,has been retained by ...ts,Peter G. Ballas MD, who has a thriving practice...highly regarded nationally as one of the foremost,...ducts. He is currently introducing Artefill (R), t...
...tes Dblur,s Software Lens(TM) Technology Into its ...YA, Israel, February 11 Dblur, the developer of,S...ategic cooperation with,STMicroelectronics (NYSE: ...The product portfolio should include a 3.2Mp, 1.75...
Other Medicine News:Health News:Neurobiological Technologies Reports Second Quarter Financial Results 2Health News:Neurobiological Technologies Reports Second Quarter Financial Results 3Health News:Neurobiological Technologies Reports Second Quarter Financial Results 4Health News:Neurobiological Technologies Reports Second Quarter Financial Results 5Health News:Two Little Hands Productions, Creators of Popular Children's TV Series Signing Time, Debuts Second Season at This Year's Toy Fair 2008 2Health News:Mybank Goes Live With Misys Equation to Support Rapid Growth and Meet Future Regulatory Requirements 2Health News:St. Conti Communications to Help Adjust Chiropractor Messaging and Communications 2Health News:Leading Cosmetic Dermatologist, Peter G. Ballas II MD, Retains Kay Renz Public Relations to Promote his Practice and New Skincare Line 2Health News:Dblur Concludes Licensing Deal With STMicroelectronics 2
High Lite Convertible
High Lite Classic
High Beam Classic
...nalyzer is a semi-automated benchtop instrument fo...nQuick is designed to analyze and generate results...k 8+ urine test strips. The UrinQuick analyzes the...y. Test results are available in conventional, S.I...
Medicine Products: